Wu et al., 2013 [81]

TNF inhibitor (etanercept or monoclonal antibody)

Myocardial infarction

Etanercept: 976; Monoclonal antibody: 217; Topical therapy: 5075

Hazard ratio (compared to topical agents): Etanercept:

0.53 (95% CI 0.31 - 0.92); Monoclonal antibody: 0.25 (95% CI 0.06 - 1.03)

United States/

Retrospective cohort study

Wu et al., 2014 [82]

TNF inhibitor

Myocardial infarction

Psoriasis (treated with TNF inhibitor): 846; Psoriasis

(not treated with TNF inhibitor): 7172

Hazard ratio (compared to psoriasis patients not treated with TNF inhibitors):

0.26 (95% CI 0.12 - 0.56)

United States/

Retrospective cohort study

Wu et al., 2017 [83]

TNF inhibitor

Major cardiovascular events (myocardial

infarction, stroke or

transient ischemic attack, unstable angina)

TNF inhibitor: 9148; Methotrexate: 8581

Hazard ratio (compared to methotrexate): Major cardiovascular event:

0.55 (95% CI 0.45 - 0.67) Myocardial infarction: 0.49 (95% CI 0.34 - 0.71);

Stroke or TIA: 0.55 (95% CI 0.42 - 0.71);

Unstable angina: 0.58 (95% CI 0.41 - 0.82)

United States/

Retrospective cohort study